Active substance
Pertuzumab trastuzumab and hyaluronidase
- US FDA 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PHESGO | 1,200MG;600MG;30,000UNITS; 600MG;600MG;20,000UNITS | injectable · subcutaneous | GENENTECH INC | Prescription | 29 Jun 2020 |
Safety signals and safety-related labeling changes
- US FDA 22 Nov 2024 PHESGO — safety-related labeling change
Labeling sections changed: Adverse Reactions
All safety entries for pertuzumab trastuzumab and hyaluronidase →
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.